12:00 AM
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BVT: Completed Phase II enrollment

CRO Ergomed completed enrollment of 120 patients in a Phase II trial evaluating oral BVT.115959. CBT Development, a virtual company between venture investors Avlar BioVentures and Excalibur Fund Managers,...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >